ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

Hollings Cancer Center at MUSC Wins NCI Designation

March 6, 2009

OD Contract Concepts Okayed

October 17, 1986

Intense Therapies Better Than Lower Dose For AML

November 26, 2004

In Brief: NIH Budget Cut Being Considered, Threatening NCI’s Plan For Reaching Year 2000 Goals

December 13, 1984

NCi Advisors Approve New SPORE Grant Program In Cancer Communications.

December 1, 2000

NCI, Groups Disagree Over repayment, McIntyre: NCA Could Examine Relationship of Groups To NCI

December 9, 1994